Baxter to end Alzheimer's trial of Gammagard

05/8/2013 | Yahoo

Baxter International said it is stopping Phase III trials of Gammagard as an Alzheimer's disease drug after it failed to ameliorate mental decline and functional ability in patients. Gammagard, also known as intravenous immunoglobulin, was the only Alzheimer's treatment in Phase III development. The firm said it will re-evaluate its Alzheimer's program and make a decision after analyzing the trial's full results.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN